Immuno-Oncology | Specialty

Burtness Discusses Next Steps With Immunotherapy in Head and Neck Cancer

September 19th 2017

Barbara A. Burtness, MD, discusses the current role of immunotherapy in head and neck cancer and potential combination regimens on the horizon.

Dr. Levine on Immunotherapy for Endometrial Cancer

September 19th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Expert Highlights Immunotherapy Potential in Ovarian Cancer

September 19th 2017

Dmitriy Zamarin, MD, PhD, discusses immunotherapy for patients with ovarian cancer.

Dr. Welling on CheckMate-040 Trial of Nivolumab in HCC

September 17th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

Dr. Welling on Incorporating Immunotherapy Into HCC Paradigm

September 16th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).

Mounting Excitement in HCC Examined at ILCA Meeting

September 16th 2017

Theodore H. Welling, MD, shares insight on the top presentations at the ILCA meeting, and how he believes the future will look for the treatment of HCC.

Dr. Montal on Systemic Therapy Advancements in HCC

September 16th 2017

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses advancements regarding systemic therapies in the field of hepatocellular carcinoma (HCC).

PROSTVAC Misses Phase III Goal in Prostate Cancer

September 15th 2017

PROSTVAC with or without GM-CSF was deemed unlikely to demonstrate an improvement in overall survival compared with placebo for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

Mixed Results for Pembrolizumab in Phase III HNSCC Study

September 13th 2017

Pembrolizumab (Keytruda) reduced the risk of death compared with standard of care therapy in patients with relapsed/metastatic head and neck squamous cell carcinoma, but the difference fell just shy of statistical significance.

Nivolumab Superior to Ipilimumab as Adjuvant Therapy for Stage III/IV Resected Melanoma

September 12th 2017

Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.

Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

September 11th 2017

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

Combination Lenvatinib/Pembrolizumab Has Antitumor Activity in Metastatic Clear Cell RCC

September 11th 2017

Lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) demonstrated promising antitumor activity in patients with metastatic clear cell renal cell carcinoma.

Pembrolizumab Shows Greater Long-Term Benefits Versus Chemo for Urothelial Carcinoma

September 10th 2017

Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.

Neoadjuvant Nivolumab Reduces Tumor Size Regardless of HPV Status in Head and Neck Cancer

September 10th 2017

Two doses of nivolumab given about 1 month prior to surgery are well tolerated and reduces tumor size in about half of patients with squamous cell carcinoma of the head and neck.

Nab-Paclitaxel Alone and With Durvalumab Shows Promise in NSCLC

September 9th 2017

Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.

Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy

September 9th 2017

A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.

Emerging Approaches in Liver Cancer

September 8th 2017

Biomarkers in Liver Cancer

September 8th 2017

Immunotherapy in Liver Cancer

September 8th 2017

Ongoing Clinical Trials in Second-Line HCC

September 8th 2017